Psoriasis Clinical and Non-Clinical Studies, Therapeutic Pipeline Analysis, and Emerging Therapies | Key Companies – Dermavant, UCB, Eli Lilly, Pfizer, Arbor Pharma, Boehringer Ingelheim, and Others

Psoriasis Clinical and Non-Clinical Studies, Therapeutic Pipeline Analysis, and Emerging Therapies | Key Companies - Dermavant, UCB, Eli Lilly, Pfizer, Arbor Pharma, Boehringer Ingelheim, and Others

“Delveinsight Business Research LLP”
Psoriasis Pipeline Insight, 2021″ report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Psoriasis Market.

The Psoriasis Pipeline report embraces in-depth commercial and clinical assessment of the Psoriasis pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Psoriasis collaborations, mergers, acquisition, funding, designations, and other product-related details.

Psoriasis Pipeline Analysis

Psoriasis Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Psoriasis with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Psoriasis Treatment.

  • Psoriasis key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Psoriasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Psoriasis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Psoriasis Therapeutics Landscape

The dynamics of the Psoriasis market is anticipated to change in the coming years owing to the expected launch of emerging therapies. 

Several companies across the globe are thoroughly working toward the development of new treatments and devices which are expected to change the current market scenario for Psoriasis. 

Key companies in the Psoriasis Market include:

  • UCB

  • Eli Lilly and Company

  • Boehringer Ingelheim

  • Akros Pharma Inc.

  • Kadmon Pharmaceuticals

  • Pfizer

  • Arbor Pharmaceuticals

  • Dr. Reddy’s Laboratories 

  • Dermavant

And several others.

Psoriasis Therapies covered in the report includes:

  • Bimekizumab 

  • Mirikizumab 

  • BI 730357 

  • JTE-451

  • KD025

  • PF-06826647

  • XP23829 

  • Tapinarof 

And many more.

Request for Sample Pages @ Psoriasis Emerging Therapies and Key Companies

Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Psoriasis.    

  • In the coming years, the Psoriasis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. 

  • The companies and academics are working to assess challenges and seek opportunities that could influence Psoriasis Research & Development. The therapies under development are focused on novel approaches to treat/improve the disease condition.

  • A detailed portfolio of major pharma players who are involved in fueling the Psoriasis treatment market. Several potential therapies for Psoriasis are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Psoriasis market size in the coming years.  

  • Our in-depth analysis of the Psoriasis pipeline assets (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities. 

Download Sample Pages @ Psoriasis Therapeutics Assessment

Table of Content

1. Report Introduction

2. Psoriasis 

3. Psoriasis Current Treatment Patterns

4. Psoriasis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Psoriasis Late Stage Products (Phase-III)

7. Psoriasis Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Psoriasis Discontinued Products

13. Psoriasis Product Profiles

14. Psoriasis Key Companies

15. Psoriasis Key Products

16. Dormant and Discontinued Products

17. Psoriasis Unmet Needs

18. Psoriasis Future Perspectives

19. Psoriasis Analyst Review  

20. Appendix

21. Report Methodology

*The table of contents is not exhaustive; the final content may vary. 

Visit to get the sample report:

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States